Google spinoff Isomorphic Labs is in a race to shake up the long, painful road to cancer-beating drugs (www.businessinsider.com)

Isomorphic Labs, a Google DeepMind spinoff led by CEO Demis Hassabis, is aiming to revolutionize cancer drug development through advanced AI technology. With a mission to develop drugs that could potentially cure cancer, the company is leveraging breakthroughs from AlphaFold, DeepMind's groundbreaking protein-mapping AI. President Max Jaderberg emphasized that the internal innovation rate has accelerated, and Isomorphic is refining its "drug design engine" to predict how drug molecules interact within the body. The goal is to enable precise drug engineering, minimizing dosages and reducing side effects, while bypassing some traditional trial-and-error hurdles in drug development. The significance of Isomorphic Labs lies in its ambitious approach to address the historically slow and challenging process of drug discovery. By using AI to model complex biochemical interactions and predict molecular behavior, Isomorphic aims to create a comprehensive drug design engine capable of tackling various diseases beyond just cancer. Though the journey from AI prototypes to FDA-approved drugs presents substantial challenges, Jaderberg expressed confidence in their approach amidst a competitive landscape that includes rivals such as OpenAI and Anthropic. The company’s strategy focuses on genuine drug development for patients rather than hype, positioning itself as a "SpaceX for drug discovery" with the vision of drastically improving treatment timelines and efficacy.